On our screens:Stocks with no debtCheap stocks by free cash flow yieldQuality compoundersQuality at a reasonable price
The financials
ResMed by the numbers
ResMed (RMD) reported revenue of $1.43B in Q3 2026 (quarter ended Mar 31, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 62% and net income of $399M (28% of revenue). For the full year FY2025, revenue was $5.15B (+9.8% year on year) and net income $1.40B. Its largest product in Jun 2026 was Sleep And Breathing Health at $1.29B, 88% of the disclosed total, well ahead of Residential Care Software at 12%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $1.43B | $1.29B | +11% |
| Gross profit | $891M | $766M | +16% |
| Operating income | $500M | $426M | +17% |
| Net income | $399M | $365M | +9.2% |
| Diluted EPS | $2.74 | $2.48 | +10% |
| Product | Revenue | Share |
|---|---|---|
| Sleep And Breathing Health | $1.29B | 88% |
| Residential Care Software | $172M | 12% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.46B (+2.3%)
Sleep And Breathing Health grew +9.4% year on yearResidential Care Software +2.9% year on year
Segment Latestquarter on quarteryear on year
- Sleep And Breathing Health$1.29B$1.29BQoQ +2.5%year on year +9.4%+2.5%+9.4%
- Residential Care Software$171.9M$171.9MQoQ +0.60%year on year +2.9%+0.60%+2.9%
Medical Instruments & Supplies
The closest names by size in the same industry